Neutralization of autoantibodies

Neutralization of autoantibodies" is **not a molecule or receptor**, but rather a therapeutic strategy aimed at inactivating or removing harmful autoantibodies from circulation. Autoantibodies are antibodies produced by the immune system that mistakenly target the body's own tissues, contributing to autoimmune diseases and exacerbating certain infections. The neutralization process can involve agents such as aptamers (e.g., BC 007), which bind specifically to pathogenic autoantibodies—such as those targeting G-protein-coupled receptors—and prevent them from exerting their pathological effects[2]. Another approach involves engineered decoy proteins that sequester neutralizing type I interferon autoantibodies, thereby restoring normal immune function in affected patients[3]. This strategy is not itself a molecular target but describes an intervention against disease-causing immunoglobulins.

Aptamer-mediated binding and neutralization of pathogenic autoantibodies; Decoy proteins to sequester and deplete pathogenic autoantibodies.